

- Hormone therapy
myocardial infarction and, 109
osteoporosis and, 762t, 763
postmenopausal, 708
systemic lupus erythematosus and, 784-785
Women's Health Initiative and, 763
- Horner syndrome, 1003
cluster headache with, 997
lung cancer and, 595
- Hospice, 1121
- Hospital-acquired pneumonia (HAP), 255
- Hot flash, in menopause, 707-708
- Housekeeping genes, 5
- Howship's lacunae, 733-734
- HPO. *see* Hypertrophic pulmonary osteoarthropathy (HPO).
- Human bites, 887-889
treatment for, 890
- Human chorionic gonadotropin (HCG),
testosterone secretion and, 652
- Human disease, molecular basis of, 2-14
deoxyribonucleic acid and the genome, 2
gene mapping and the Human Genome Project,
8-9
genetic sequence variation, population diversity,
and genetic polymorphisms, 6-8
introduction, 2
mutant genes, identification of, 9-14, 11t
genes, and human disease, 11-12
genome editing, 13
molecular diagnostics, 10-11
molecular medicine, 12
pharmacogenetics, 13
regenerative medicine, 13-14
ribonucleic acid, synthesis of, 2-4, 3f
- Human epidermal growth factor receptor 2
(HER2), 598
- Human genome project, 8-9
- Human hemoglobins, structure and distribution
of, 502t
- Human immunodeficiency virus (HIV), 816
polyarteritis nodosa in, 796
- Human immunodeficiency virus (HIV) infection,
927-942
acute retroviral syndrome, 930, 930t
adrenal reserve in, 643
antiretroviral medications by class, 933t
antiretroviral therapy for, 934t
change of, 934
drug regimens in, 933-934
goal of, 933
initiation of, 934-935
cachexia in, 936
constitutional symptoms of, 935-936
diagnosis and differential diagnosis of, 931-932
diarrhea in, 938
early immunodeficiency, 931
epidemiology of, 927
esophageal disease, 936
fever of unknown origin in, 841
first impacts of, 931
gastrointestinal diseases in, 938
hepatitis in, 938
infections in. *see also* specific infections
CD4 counts and, 931
cutaneous, 936
- Human immunodeficiency virus (HIV) infection
(Continued)
oral, 936
prophylaxis against opportunistic, 934-935
pulmonary diseases, 936-937
screening for associated, 932
initial assessment of, 935
management of specific clinical manifestations
of, 935-941
musculoskeletal and rheumatologic disorders,
941
natural history of, 930f
nephropathy in, 317, 941
nervous system diseases, 939-940
aseptic meningitis, 940
chronic meningitis, 940
neuroanatomic classification of, 939t
neurologic complications of, 939t
occupational exposure to, 941-942
pathology of, 928-930
prevention of, 941-942
primary, 844
for primary and secondary prophylaxis for
persons with, 935t
prognosis of, 942
renal disorders in, 941
screening of women for, 702t
spectrum of disease associated with, 931
thrombocytopenia in, 550
transmission of, 927
treatment cascade, 928f
treatment of, 932-933
viral load in, 930
viral replication, 929f
in women, 712
- Human leukocyte antigen (HLA)
B27, spondyloarthritis and, 775
stem cell transplantation and, 481
- Human papillomavirus (HPV), 925
cervical cancer and, 581-582
head and neck cancer and, 613
in HIV-infection patients, 933
- Human platelet antigen-1b (HPA-1b), 566t
- Human T-cell lymphotropic virus type 1
(HTLV-1), 522
- Humoral hypercalcemia of malignancy, 748
- Humoral immunity defects, 946
- Humoral response, 829
- Hungry bone syndrome, 753-754
- Huntington's disease, 1019-1020
phenocopies of, 1020
- Hyaline membranes, in acute respiratory distress
syndrome, 262, 262.e1f
- Hyaluronate, intra-articular, in osteoarthritis, 807
- Hydatid disease, 957
- Hydatidiform mole, hyperthyroidism and, 637
- Hydralazine
for heart failure, 63-64
lupus caused by, 231
for preeclampsia, 177
reduction of afterload by, 20
- Hydrocele, 727-728
- Hydrocephalus
intracerebral hemorrhage with, 1043
noncommunicating, 965-966
normal-pressure, dementia in, 983
- Hydrocodone, 1118, 1119t
- Hydrocortisone, for adrenal insufficiency, 645
- Hydrodensitometry, 677
- Hydrogen, in acute kidney injury, 361.e1t
- Hydromorphone, 1118-1120, 1119t
- Hydronephrosis, 360, 355.e1f
- Hydroxyapatite, 732, 738
- γ -Hydroxybutyrate (GHB), 1133
- Hydroxychloroquine, for rheumatoid arthritis, 774t
- 1 α -Hydroxylase, 287-288
- 11 β -Hydroxylase deficiency, 646, 649
- 17-Hydroxylase deficiency, 171
- 17 α -Hydroxylase deficiency, 649
- 21-Hydroxylase deficiency, 646
- Hydroxyurea
for essential thrombocythemia, 491-492, 569
for polycythemia vera, 490-491
for primary myelofibrosis, 493
for sickle cell disease, 512
- Hyperaldosteronism
glucocorticoid-remediable, 649
secondary, 647t. *see also* Aldosteronism
- Hyperbilirubinemia, 441. *see also* Bilirubin.
conjugated, 444t, 446-448
etiology of, 445
unconjugated, 444t, 445-446
- Hypercalcemia, 741-744
cancer-associated, 620
in breast cancer, 620
chronic and acute renal failure with, 743-744
differential diagnosis of, 741-744
disorders associated with, 742t
familial hypocalciuric, 743
in granulomatous disorders, 743
head and neck cancer and, 613
in hyperproteinemia, 744
in hyperthyroidism
endocrine disorders and, 743
primary and tertiary, 742-743
in immobilization, 743
malignancy-associated, 741-742
medications causing, 743
in milk-alkali syndrome, 743
in parenteral nutrition, 744
pathophysiology of, 741
with pheochromocytoma, 743
symptoms and signs of, 741
treatment of, 744
with VIPomas, 743
- Hypercalciuria, 338-339
in sarcoidosis, 229
- Hypercapnia, primary, 312
- Hypercapnic encephalopathy, 312
- Hypercarbia, 212
- Hyperchloremic metabolic acidosis, 307-308, 307f
in chronic kidney disease, 363
- Hypercholesterolemia
familial, 694-695
in hypothyroidism, 638
- Hypergastrinemia, 413-414
- Hyperglycemia, 657
hyponatremia and, 299-300
parenteral nutrition and, 687-688
in sepsis, 850
- Hyperglycemic hyperosmolar state (HHS),
669-670